Hear from the experts about the RINVOQ clinical trials
[Affiliates to insert drivers to local asset]
SELECT-COMPARE clinical trial results
Hear Dr. Roy Fleischmann discuss RINVOQ study results in patients with moderate to severe active RA with an inadequate response to methotrexate.1–3
[Affiliates to insert drivers to local asset]
SELECT-MONOTHERAPY clinical trial results
Hear Professor Paul Emery discuss RINVOQ monotherapy study results in patients with moderate to severe active RA and an inadequate response to a stable dose of methotrexate.1,4
[Affiliates to insert drivers to local asset]
SELECT-BEYOND clinical trial results
Hear Dr. Bernard Combe discuss RINVOQ study results in patients with moderate to severe active RA and an inadequate response to bDMARDs.1,5
[Affiliates to insert drivers to local asset]
SELECT-EARLY clinical trial results
Hear Dr. Stephen Hall discuss study results in MTX-naive patients with moderately to severely active RA.6
[Affiliates to insert drivers to local asset]
Integrated safety analysis results
Hear Professor Kevin Winthrop discuss results from an integrated safety analysis from the SELECT Phase 3 clinical program in patients with moderate to severe RA.7
Safety Information1
References
- RINVOQ [Summary of Product Characteristics]. AbbVie Deutschland GmbH & Co. KG; May 2021.
- Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788-1800. doi:10.1002/art.41032
- Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response [published online July 30, 2019]. Ann Rheum Dis. doi:10.1136/annrheumdis-2019-215764
- Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303-2311. doi:10.1016/S0140-6736(19)30419-2
- Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513-2524. doi:10.1016/S0140-6736(18)31116-4
- van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naïve patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): a randomized, double-blind, active-comparator, multi-center, multi-country trial. Arthritis Rheumatol. 2020;72(10):1607-1620. doi:10.1002/art.41384
- Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020;80(3):304-311. doi:10.1136/annrheumdis-2020-218510